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Abstract
Liver tumours are fortunately rare in children. Benign tumours such as haemangiomas and cystic mesenchymal
hamartomas are typically seen in infancy, often before 6 months of age. After that age, malignant hepatic tumours
increase in frequency. The differentiation of a malignant from benign lesion on imaging can often negate the need
for biopsy. Ultrasound is currently the main screening tool for suspected liver pathology, and is ideally suited for
evaluation of hepatic lesions in children due to their generally small size. With increasing research, public awareness
and parental anxiety regarding radiation dosage from CT imaging, MRI is now unquestionably the modality of
choice for further characterisation of hepatic mass lesions.
Nevertheless the cost, length of imaging time and perceived complexity of a paediatric liver MR study can be
intimidating to the general radiologist and referring clinician. This article outlines standard MR sequences utilised,
reasons for their utilisation, types of mixed hepatocyte specific/extracellular contrast agents employed and imaging
features that aid the interpretation of paediatric liver lesions. The two commonest paediatric liver malignancies,
namely hepatoblastoma and hepatocellular carcinoma are described. Differentiation of primary hepatic
malignancies with metastatic disease and mimickers of malignancy such as focal nodular hyperplasia (FNH) and
hepatic adenomas are also featured in this review..
Imaging should aim to clarify the presence of a lesion, the likelihood of malignancy and potential for complete
surgical resection. Reviewing and reporting the studies should address these issues in a systematic fashion whilst
also commenting upon background liver parenchymal appearances. Clinical information and adequate patient
preparation prior to MR imaging studies help enhance the diagnostic yield.
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Background
Primary hepatic tumours account for only 1–2 % of all
childhood cancers [1]. After 6 months of age a newly identi-
fied liver mass in a child will be malignant in the majority of
cases [2]. The commonest primary malignant liver tumours
in childhood include hepatoblastomas and hepatocellular
carcinomas (HCC) with the remainder comprising com-
paratively rarer sarcomas (e.g. undifferentiated embryonal
sarcomas, angiosarcomas and biliary rhabdomyosarcomas)
[3]. Metastatic liver lesions in children, like in adults, are
commoner than isolated primary hepatic lesions and
commonly originate from neuroblastoma or Wilms’
tumours [4].
The aims of imaging are therefore directed at answer-
ing three main issues – confirming the presence of a
liver lesion(s), defining it’s precise extent and whether it
can be confidently characterised. The latter two findings
will govern the need for biopsy or the approach for
potential surgical management. Accurate radiological
assessment is crucial at this stage, as it may negate the
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need for biopsy with benign processes [5], or alterna-
tively direct further imaging such as a chest CT for
evaluation of potential pulmonary metastases. The ex-
tent and number of malignant lesions also provides use-
ful information in guiding the need for adjuvant
chemotherapy and/or suitability for listing the patient
for potential liver transplantation.
This article will describe the method by which to ad-
dress the aforementioned factors whilst providing a gen-
eral overview of the imaging findings in the two
commonest malignant paediatric hepatic tumours and
pitfalls in their diagnosis and follow-up imaging.
Imaging approach
Ultrasound examination is the principal screening mo-
dality for identification of a suspected intra-abdominal
mass in a child. Despite its ability to characterise the
presence, size, solid component and vascularity of a liver
mass - the mere presence of a lesion without an already
established diagnosis should form the basis for further
imaging with MRI. In some European centres, contrast
enhanced ultrasound (CEUS) techniques may be
adopted at this stage to help characterise likelihood of
malignancy [6] and may inform the level of urgency for
further MR assessment. CEUS is unfortunately not li-
cenced for use in children and, although all the evidence
suggests it is safe to use in young patients, it is not
widely used as a consequence [7]. In addition, ultra-
sound is limited by its small field of view and subse-
quent difficulty in determining an accurate number or
extent of liver lesions.
The advantages in utilising MRI for liver lesions in-
clude the lack of ionising radiation, good multi-planar
spatial resolution (which in particular facilitates surgical
planning) and excellent soft tissue characterisation.
Nevertheless not all medical institutions possess the re-
sources required to perform MRI studies in paediatric
patients. This may be due to a variety of factors includ-
ing cost, longer scanning times, the need for sedation in
young patients, lack of local radiological expertise and
machine availability. Where these limitations cannot be
overcome or where urgent treatment and diagnosis are
required, CT imaging may be performed, although the
increased radiation burden and reduced soft tissue con-
trast makes it much less ideal [8]. If CT were performed
to assess a hepatic mass lesion, we would advocate that
a single portal venous phase CT is generally sufficient.
In a child the size, vascularity and anatomical position of
the lesion can all be assessed in the portal venous phase,
and the other phases (non-contrast, arterial, delayed)
add little diagnostic information [9].
When performing MR studies in children, adequate
patient preparation can make a significant difference to
the quality of the resultant images. Ideally patients
should have nothing by mouth for 4 h prior to the study.
Sedation or general anaesthesia may be needed (usually
for those of ages less than 6–7 years) if the child is un-
able to hold his or her breath for longer than 20 s or if
he or she cannot remain still for the approximately
45 min scan [10]. Occasionally, play specialists (Child
Life) can be utilised in co-operative children as young as
5 years old to prevent sedation or general anaesthesia.
Coils that are used can vary according to the size of the
patient, but the smallest possible coil to achieve ad-
equate coverage is recommended, and 8–32 phased-
array surface channel coils are currently standard [11].
Despite the paucity of studies comparing diagnostic
yield in liver lesion detection when utilising a 1.5 T ver-
sus 3 T magnet, our experience and those of other insti-
tutions are that a higher magnet strength produces
better spatial resolution and is preferable in younger
children when a choice exists [12, 13].
The length of the study can be variable and will be in
part determined by patient co-operation (if un-sedated)
and type of intravenous contrast agent used. Contrast
agents for paediatric liver imaging fall predominantly
into two subclasses, namely the typical extracellular
agents (ECAs) used in most abdominal imaging, and
mixed hepatocyte specific/extracellular agents. Both con-
trast agent subclasses include gadolinium-based media,
containing a central gadolinium ion bound to a specific
ligand, which determines the properties and anatomical
distribution of the agent.
Mixed hepatocyte specific/extracellular agents are ac-
tively transported into hepatocytes and partially excreted
through the biliary system. These therefore permit a
more delayed ‘hepatobiliary phase’ imaging post admin-
istration allowing visualisation of the central biliary anat-
omy, thereby prolonging the length of the examination.
Although routinely utilised with an excellent safety pro-
file [14], they are technically ‘off label’ for use in paediat-
ric liver imaging.
Examples of the two commonly used agents in this
subclass include gadoxetate disodium (Gd-EOB-DTPA,
marketed as Eovist/Primovist; Bayer HealthCare,
Leverkusen, Germany) and gadobenate dimeglumine
(Gd-BOPTA, marketed as Multihance; Bracco Imaging,
Milan, Italy). Approximately 50 % of gadoxetate and
3–5 % of gadobenate is excreted through the biliary sys-
tem, with the remainder excreted via the kidneys. Hepa-
tobiliary phase imaging can be performed 20 min after
injection of gadoxetate and 40 min after injection of
gadobenate [15]. Both agents have been shown to help
improve diagnostic confidence in identification of liver
lesions in children, and in differentiating them from focal
nodular hyperplasia (FNH) in particular [13, 16–18]. At
our collective institutions, mixed hepatocyte specific/
extracellular agents are routinely used during MR
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examinations in all patients with known or suspected hep-
atic lesion(s).
Standard liver imaging protocols usually consist of
axial T1, axial (+/− coronal) T2 weighted fast/turbo spin
echo sequences, axial 3D gradient recalled echo (GRE)
sequences (out/in phase) or T1 DIXON GRE (to provide
out/in phase with fat suppressed and water supressed
images), axial (+/− coronal) balanced steady state free
precession (SSFP), axial diffusion weighted images
(DWI, b values 0, 100 and 800 s/mm2) and dynamic post
contrast 3D or 4D GRE sequences (obtained in early
arterial (10s after injection), arterial (at 20–30s after
injection), portovenous (40–60s) and equilibrium
(5 min)) and a delayed hepatobiliary phase [11, 19]. In
order to save time, the pre-contrast T1 weighted images
can be acquired as the first sequence, with the remaining
sequences performed after contrast injection, and the
delayed post-contrast hepatobiliary phase T1 weighted
imaging performed last [18]. This capacity of multiple
varied phases of contrast enhancement, with no
additional radiation burden, is a significant reason
why MRI is preferred to CT when evaluating liver
lesions in children.
An informative article by Meyers et al. [11] details the
paediatric liver MR sequences acquired at Cincinnati
Children’s Hospital using gadoxetate disodium. The
imaging protocol used at The Hospital for Sick Children,
Toronto, where gadobenate dimeglumine is adminis-
tered, can be found in the article by Chavhan et al. [18].
The clinical request form
Prior to reviewing the imaging, crucial information
gleaned from the clinical request form can already guide
the radiologist towards a list of potential differential
diagnoses [4]. Age plays a key factor as hepatoblastoma,
hepatic hemangiomas, mesenchymal hamartomas and
metastatic disease from neuroblastoma or Wilms’ tu-
mours present mostly within the first 3 years of life [20]
while hepatocellular carcinoma (HCC), FNH and hepatic
adenomas occur chiefly in older children and adolescents.
Clinical tumour markers, if available to the radiologist,
are also important. The alpha-fetoprotein (AFP) level in
particular is key, as this is elevated in the majority of pa-
tients with hepatoblastomas and HCCs [21, 22]. It is
noteworthy here too that it has recently become appar-
ent that some ‘non-AFP secreting hepatoblastomas’, pre-
viously deemed higher risk disease, are actually hepatic
rhabdoid tumours [23]. AFP has also been demonstrated
to be an excellent marker in predicting tumour recur-
rence during follow-up with one 10 year retrospective
study reporting no imaging identifiable relapses from
hepatoblastoma without an abnormal elevation of serum
AFP levels [24].
Patients with certain background medical histories
(such as Beckwith Wiedemann syndrome, Familial aden-
omatous polyposis (FAP)) are prone to develop hepato-
blastomas, whereas those with underlying glycogen
storage diseases, biliary atresia, alpha-1 anti-trypsin defi-
ciency and tyrosinaemia are prone to developing HCC.
Children with a history of a treated solid tumour with
chemotherapy and/or radiation therapy have also been
shown to have a predisposition towards the development
of FNHs [25].
Finally, it is also important to consider whether the pa-
tient is suffering from background liver disease, such as de-
compensated liver cirrhosis, which will reduce the level of
hepatocyte uptake and biliary excretion of mixed hepato-
cyte specific/extracellular contrast agents [26] and hinder
image interpretation. Unfortunately the degree to which
this occurs does not appear to correlate to serum markers
of liver function [27], so cannot be accurately predicted.
Review of imaging/Useful sequences
After reviewing the clinical information, a systematic ap-
proach should be adopted during image review and report-
ing, ensuring that the following issues are addressed:
1) Lesion presence, number, anatomical location and
imaging characteristics,
2) Background liver parenchymal appearances,
3) Evidence of metastatic spread, vascular or biliary
complications,
4) Other non- hepatobiliary findings (such as presence
of primary suprarenal or renal mass and/or
lymphadenopathy).
In identification of liver lesions, many authors have
purported the usefulness of the low b-value diffusion
weighted images (b = 50–100 s/mm2), with lesions being
more apparent on this sequence than on the usual T2
weighted sequences [28–30] (Fig. 1).
The most crucial sequences in lesion differentiation
include the pattern of contrast enhancement during
dynamic and delayed hepatobiliary phases of imaging
[11, 31]. Some typical and atypical findings of the com-
monest paediatric liver lesions are described later.
In adult patients, the use of ADC values in the charac-
terisation of liver lesions has been limited [32]. There is
a paucity of paediatric studies on this topic and therefore
care should be taken when relying on diffusion-weighted
characteristics for purposes of differentiating benign
from malignant lesions [33].
Interpretation of the background liver parenchyma for
diffuse liver disease, steatosis, fibrosis and iron depos-
ition should also not be forgotten. Newer techniques
such as MR elastography can help to quantify the degree
of fibrosis, if needed, albeit little used in children to date
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[34, 35]. Multi-echo gradient imaging is helpful in asses-
sing features such as steatosis and iron deposition (side-
rosis), with hepatic siderosis appearing more
pronounced in image sequences obtained at longer TE
times, as demonstrated by loss of signal intensity within
the liver parenchyma [36, 37].
Paediatric liver tumour characteristics
Hepatoblastoma
A hepatoblastoma is the most common primary hepatic
malignancy in the paediatric population. A typical hepa-
toblastoma on MRI is heterogeneously hyperintense on
T2 weighted images, hypointense on T1 weighted im-
aging and enhances in a heterogenous fashion, although
remaining on the whole hypointense when compared to
the background liver parenchyma in all phases of en-
hancement [11, 38] (Fig. 2). Calcification within the
mass is present in 50 % of cases and haemorrhage and
necrosis may also occur in variable amounts leading to
the heterogenous signal intensity [4].
Hepatoblastomas may also demonstrate atypical radio-
graphic and clinical features [11]. Small cell undifferenti-
ated subtypes of hepatoblastomas may not be associated
with raised AFP levels [39]. Meyers et al. [11] report two
cases of hepatoblastomas with avid enhancement during
the hepatobiliary phase of imaging which, on pathology
were reported to display teratoid features. The authors
propose this enhancement may possibly relate to in-
ternal functioning hepatocytes. We have also noted in a
few hepatoblastoma cases with fetal histology that the
tumours have accumulated the hepatocyte specific agent,
perhaps because these tumours contain some persisting
hepatocyte functioning also.
Malignant paediatric hepatic tumours (predominantly
hepatoblastoma, but also HCC) are staged prior to com-
mencement of therapy according to the PRETreatment
EXTent of tumour (PRETEXT) system, designed by the
International Childhood Liver Tumor Strategy Group
(SIOPEL) [40]. The staging has been shown to correlate
closely to prognosis and survival (for children with hepa-
toblastoma and fibrolamellar hepatocellular carcinoma
[41]) and has a good inter-observer reproducibility [42].
The latest version of this staging system, established in
2005, requires the radiologist to delineate the number of
anatomical sections that are involved and those that are
free of tumour. There are 4 anatomical sections de-
scribed in the staging system which are divided based on
groupings of the Couinaud’s segmentation of the liver.
The PRETEXT score represents the number of contigu-
ous sections that must be resected to completely excise
the tumour.
Additional imaging information for PRETEXT staging
including hepatic, portal venous and IVC involvement
(Fig. 3), lymph node enlargement, tumour rupture, pres-
ence of distant metastases and, albeit rare, extrahepatic
abdominal spread of disease should be commented
upon. If pre-operative chemotherapy has been instigated,
it is recommended that repeat imaging be performed
prior to any surgical intervention, and restaged in the
same manner, recorded as the ‘POSTEXT’ staging [40].
Hepatocellular Carcinoma (HCC)
HCC is the most common primary hepatic malignancy in
adolescence and the second most common primary paedi-
atric malignancy of the liver. Paediatric HCC differs from
adult-type HCC in several important ways. First, pre-
existing liver disease is only present in 30–50 % of paediat-
ric patients [38, 43]. While cirrhosis is the most common
risk factor for developing HCC in adults, it is much less
common in children living in the Western world, occur-
ring in only 20–25 % of patients [38]. In addition, there
are molecular differences of paediatric HCC including a
higher rate of c-met gene mutations, a higher rate of loss
of heterozygosity on chromosome 13q, and lower levels of
cyclin D1 [38].
Fig. 1 Multiple areas of focal nodular hyperplasia in a 17 year old patient with prior history of right hepatectomy for hepatoblastoma. (a) Diffusion-
weighted imaging (b = 50 s/mm2) allows for improved detection of the multiple liver lesions than (b) the axial T2-weighted fat-saturated sequence
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Fig. 2 Hepatoblastoma in a 4 year old patient. The (a) axial T1-weighted fat saturated imaging of the lung bases demonstrates multiple
pulmonary metastases. On (b) T1-weighted fat-saturated pre-contrast imaging, the hepatic mass has internal heterogenous signal intensity,
with overall hypointensity compared to background liver parenchyma. It is mildly hyperintense compared to the liver parenchyma on (c) the T2-
weighted fat saturated sequence. On (d) portal venous phase imaging, post gadobenate dimeglumine administration, the lesion has internal
heterogeneous enhancement
Fig. 3 Metastatic hepatoblastoma with inferior vena cava (IVC) and right hepatic vein thrombus (white arrows) in a 2 year old boy. After administration
of gadobenate dimeglumine, the (a) arterial phase T1-weighted fat-saturated imaging demonstrates a filling defect in the affected vessels. Thrombosis
was subsequently confirmed and identified on (b) portal venous phase post-contrast imaging on CT and (c), (d) ultrasound imaging of the IVC with
and without colour doppler overlay respectively
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Unfortunately, the prognosis for HCCs occurring in
children tends to be poorer than those observed in
adults [4], with adolescent patients more commonly af-
fected than young children [44]. Typical MRI features of
HCC include avid arterial phase enhancement with
wash-out on the portal venous phase of enhancement,
compared to the background liver parenchyma. With
hepatobiliary phase imaging, the lesion remains hypoin-
tense to adjacent liver, although rarely, atypical or early
HCCs may demonstrate enhancement [27].
The fibrolamellar variant of HCC is more commonly
seen in young adults (Fig. 4). It is hyperintense on T2
weighted sequences and hypointense on T1 weighted se-
quences compared to background liver, with some dem-
onstrating a hypointense central scar [20]. Post contrast,
these tumours tend to demonstrate arterial enhancement
with washout in the portovenous phase and remain
hypointense in the hepatobiliary phase. There is not nor-
mally any enhancement of the central scar [26].
Fibrolamellar HCC is often included in a differential
diagnosis list with focal nodular hyperplasia due to the
presence of a central stellate scar. However, it can be dif-
ferentiated from FNH based on the appearance of the
central scar and the appearance of the tumour on the
hepatobiliary phase. Fibrolamellar HCC has a hypoin-
tense scar on T2-weighted images while FNH has a
hyperintense scar on the same sequence. On the hepato-
biliary phase of enhancement fibrolamellar HCC is
hypointense to the background liver while FNH is isoin-
tense to hyperintense to the background liver.
Metastatic disease
Metastases from non-hepatic primary malignancies are
commoner than those from primary hepatic tumours in
general (such as those from Wilms’ tumours and neuro-
blastomas [44]). Liver metastases are typically hyperin-
tense on T2 weighted images (although they can also be
of intermediate signal intensity) and hypointense on
noncontrast T1 weighted images [20]. Neither hyper nor
hypovascular metastases enhance in the hepatobiliary
phase of contrast [11].
Fig. 4 Fibrolamellar variant of hepatocellular carcinoma in a 15 year old patient. The hepatic lesion is hypointense to background liver parenchyma on
(a) pre-contrast T1-weighted sequences with heterogenous internal enhancement after administration of gadoxetic acid in (b) arterial phase and (c) porto-
venous phase imaging. There is gradual washout of contrast on the (d) 5 min delayed and (e) 20 min delayed imaging. Note the excretion of contrast
material within the common bile duct allowing localisation of the mass and its relation to the biliary system, aiding surgical planning
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Neuroblastoma metastases tend to demonstrate per-
ipheral enhancement on arterial phase imaging with cen-
tral progression of enhancement and peripheral washout
on portal venous phase sequences. In some cases, they
may also remain isointense [45]. A potential pitfall may
arise when trying to differentiate such features from
multifocal infantile hemangioendotheliomas [46], how-
ever the presence of additional metastases (such as bone
lesions) or the primary tumour (which may be an ad-
renal, retroperitoneal or paravertebral mass) with MIBG
avidity and elevated levels of urinary catecholamines will
help to clinch the diagnosis.
Focal Nodular Hyperplasia (FNH) and hepatocellular
adenomas
As previously mentioned, mixed hepatocyte specific/extra-
cellular agents are useful in helping to differentiate FNHs
from other hepatic lesions. The presence of normal func-
tioning hepatocytes within the FNH allow uptake of this
contrast. There is enhancement of the FNH in the arterial
phase due to contrast material leaking from the vascular
space into the interstitial space, however during the hepa-
tobiliary phase of imaging there is active hepatocellular
uptake (depending on presence of transporter proetein
OATP1B1/3 [47]) and therefore persistent lesion enhance-
ment (Fig. 5). This feature helps to differentiate FNH from
other malignant lesions, which typically demonstrate con-
trast wash-out when compared to normal liver paren-
chyma [20] (Fig. 6).
A pitfall in interpretation may occur when trying to
differentiate FNHs from regenerative nodules, as both
can be hyperintense in the hepatobiliary phase. Whilst
pre-contrast features can sometimes be helpful in mak-
ing the differentiation, it may be difficult in scenarios
where there is haemorrhage or fatty deposition within
the FNH, or in the presence of background liver disease.
Lesions that do not conform to those of a typical FNH
therefore warrant biopsy [18].
Fig. 5 Focal nodular hyperplasia in a 14 year old female patient. The hepatic lesion is hypointense to background liver parenchyma on (a) pre-
contrast T1-weighted fat-saturated sequences. There is avid enhancement of the lesion post gadobenate dimeglumine administration in (b) the
arterial phase, with eventual homogenous enhancement of the lesion and central scar in the (c) portal venous and (d) equilibrium phases. The
delayed (e) 30 min and (f) 45 min images show the lesion enhancing to a similar intensity as the background liver parenchyma
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Hepatocellular adenomas also contain hepatocytes
(like FNH), although not malformed biliary ducts. Fat
content may be present within them, but is non-specific
for the diagnosis [46]. Currently, four subtypes of hepa-
tocellular adenomas are recognized: inflammatory, hep-
atocyte nuclear factor 1 alpha (HNF-1α) mutated, β-
catenin mutated and unclassified. Each subtype has
unique clinical, imaging and/or histopathologic findings
[48, 49]. Adenomas have variable signal characteristics
based on internal fat content, hemorrhage and histologic
subtype. It should be noted that with the exception of
the β-catenin (most commonly seen in the paediatric
population) and inflammatory subtypes, most other hepa-
tocellular adenoma subtypes are hypointense to the sur-
rounding normal liver during the hepatocyte phase
allowing radiologists to differentiate these lesions from
FNH. Inflammatory and β-catenin subtypes of adenomas
may appear iso/hyperintense during the hepatocyte phase
and can be difficult to distinguish from FNH [50, 51].
Conclusions
MR imaging for characterising paediatric liver tumours
provides excellent soft tissue contrast. The usage of
mixed hepatocyte specific/extracellular contrast agents
allows for better lesion characterisation and location,
particularly with respect to the biliary system and for
differentiating FNH from other liver lesions.
Imaging should aim to clarify the presence of a lesion,
the likelihood of malignancy and potential for complete
surgical resection. Reviewing and reporting the studies
Fig. 6 Multiple areas of focal nodular hyperplasia in a 17 year old patient with prior history of right hepatectomy for hepatoblastoma. Same
patient as in Fig. 1. On the (a) pre-contrast T1-weighted fat-saturated images, the liver lesions are not visualized. Post gadobenate dimeglumine
administration in (b) arterial phase imaging, there are multiple avidly enhancing lesions throughout the liver. These demonstrate similar internal
signal intensity to the background liver parenchyma in (c) portal venous, (d) equilibrium and (e) 40 min delayed phases of imaging. There is no
wash out of contrast material to suggest metastatic disease
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should address these issues in a systematic fashion whilst
also commenting upon background liver parenchymal
appearances. Clinical information and adequate patient
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